VivoSeq
0

Pipeline Programs

0

Active Trials

1

Companies Involved

PCOS is an early-stage landscape with 0 programs across 1 company. The most active players are Margan Biotech.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

15/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

20

clinical trials

Completed14 · 70%
Unknown status3 · 15%
Withdrawn2 · 10%
Terminated1 · 5%

Trial Activity

20 trials

The Effect of Escitalopram in PCOS
Completed·OOdense University Hospital·Phase 4·NCT05840692·40 enrolled
The Effect of Dihydroartemisinin in PCOS
Completed·SShanghai Zhongshan Hospital·Phase 4·NCT05465135·19 enrolled
N-Acetylcysteine and L-carnitine in Pcos
Completed·ZZagazig University·Phase 2·NCT03164421·164 enrolled
Letrozole Dose Increments in PCOS Patients Resistant to Letrozole
Completed··Phase 3·NCT06403488·102 enrolled
NAC in CC Resistant PCOS After LOD
Completed··Phase 2/3·NCT02775734·144 enrolled
Myo-inositol Versus Clomiphene Citrate in PCOS
Terminated·UUniversity Hospital, Ghent·Phase 4·NCT04306692·12 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)